Literature DB >> 11822930

Periconceptional exposure to efavirenz and neural tube defects.

Marco De Santis1, Brigida Carducci, Lidia De Santis, Anna Franca Cavaliere, Gianluca Straface.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11822930     DOI： 10.1001/archinte.162.3.355

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


× No keyword cloud information.
  32 in total

1.  Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.

Authors:  Susan B Brogly; Mark J Abzug; D Heather Watts; Coleen K Cunningham; Paige L Williams; James Oleske; Daniel Conway; Rhoda S Sperling; Hans Spiegel; Russell B Van Dyke
Journal:  Pediatr Infect Dis J       Date:  2010-08       Impact factor: 2.129

2.  Efavirenz pharmacokinetics during pregnancy and infant washout.

Authors:  Regis Kreitchmann; Stein Schalkwijk; Brookie Best; Jiajia Wang; Angela Colbers; Alice Stek; David Shapiro; Tim Cressey; Mark Mirochnick; David Burger
Journal:  Antivir Ther       Date:  2019

3.  First trimester exposure to antiretroviral therapy and risk of birth defects.

Authors:  Kelesitse Phiri; Sonia Hernandez-Diaz; Kate B Dugan; Paige L Williams; Judith A Dudley; Astride Jules; S Todd Callahan; George R Seage; William O Cooper
Journal:  Pediatr Infect Dis J       Date:  2014-07       Impact factor: 2.129

4.  Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.

Authors:  Eric N Ouattara; Xavier Anglaret; Angela Y Wong; Jennifer Chu; Heather E Hsu; Christine Danel; Serge Eholié; Raoul Moh; Delphine Gabillard; Rochelle P Walensky; Kenneth A Freedberg
Journal:  AIDS       Date:  2012-03-13       Impact factor: 4.177

5.  Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.

Authors:  Akihiko Saitoh; Stephen A Spector
Journal:  Futur HIV Ther       Date:  2008-01-01

6.  Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants.

Authors:  Paige L Williams; Marilyn J Crain; Cenk Yildirim; Rohan Hazra; Russell B Van Dyke; Kenneth Rich; Jennifer S Read; Emma Stuard; Mobeen Rathore; Hermann A Mendez; D Heather Watts
Journal:  JAMA Pediatr       Date:  2015-01       Impact factor: 16.193

7.  Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA.

Authors:  H E Hsu; C E Rydzak; K L Cotich; B Wang; P E Sax; E Losina; K A Freedberg; S J Goldie; Z Lu; R P Walensky
Journal:  HIV Med       Date:  2011-02       Impact factor: 3.180

8.  Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.

Authors:  Tim R Cressey; Alice Stek; Edmund Capparelli; Chureeratana Bowonwatanuwong; Sinart Prommas; Pannee Sirivatanapa; Prapap Yuthavisuthi; Chanon Neungton; Yanling Huo; Elizabeth Smith; Brookie M Best; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2012-03-01       Impact factor: 3.731

Review 9.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

10.  Evaluation and treatment of the human immunodeficiency virus-1-exposed infant.

Authors: 
Journal:  Paediatr Child Health       Date:  2004-07       Impact factor: 2.253
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.